Peptide half-life and why dosing frequency varies

Whether a peptide is dosed multiple times a day, once daily, or once weekly comes down mostly to its half-life — and modern peptides are deliberately engineered to extend it.

One of the most visible differences between peptides is how often each is dosed: some appear in protocols several times a day, some once daily, and some once weekly. The schedule is not arbitrary — it follows largely from the peptide's half-life, and much of modern peptide design is an effort to extend that half-life deliberately. This article is an educational reference to the pharmacology behind dosing frequency, not a dosing recommendation for any compound.

What half-life means

A peptide's elimination half-life is the time it takes for its concentration in circulation to fall by half. A short half-life means the compound clears quickly and concentrations swing up and down sharply between doses; a long half-life means concentrations stay more level, which allows less frequent dosing while maintaining a relatively steady presence. Half-life, not potency, is usually what sets the dosing interval.

Short half-life peptides

Native and minimally modified peptides tend to clear within minutes to a few hours. Growth-hormone-releasing peptides and analogues such as sermorelin, the GHRPs, and growth-hormone fragments fall into this category, which is why research protocols for them frequently describe daily or even multiple-times-daily administration. The short window is also why these compounds are often discussed in terms of timing relative to the body's own hormone pulses.

Engineered long half-life

The headline metabolic peptides owe their convenience to engineering that resists degradation and slows clearance. The most common technique is fatty-acid acylation: attaching a lipid chain that binds reversibly to albumin in the blood, creating a circulating reservoir that releases the peptide slowly. Semaglutide and tirzepatide use this approach and are dosed once weekly as a result. Liraglutide uses a shorter-acting version of the same idea and is dosed once daily — the same GLP-1 class, a different half-life, a different schedule.

Why the interval matters

Dosing frequency interacts with the concept of steady state — the point at which the amount entering circulation balances the amount cleared. A long-half-life peptide reaches a relatively flat steady state on infrequent dosing, while a short-half-life peptide produces peaks and troughs and so is dosed more often to keep concentrations within a useful range. None of this implies a 'best' schedule; the labelled or studied interval for a given compound reflects its specific pharmacokinetics, and that figure is what the reference pages report.

A practical consequence for anyone cross-referencing peptides is that dosing frequency is a property of the molecule, not of the goal. Two peptides studied for similar endpoints can have entirely different schedules because one was engineered for albumin binding and the other was not. The half-life noted on each reference page is therefore as important as the dose amount when comparing compounds.